Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Enovis CorporationNYSE: ENOV
Accumulated OCI · Q1 FY2026 · quarter ended Apr 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was -$103.76M, compared with -$64.99M a year earlier.
Context
- Accumulated OCI amounted to 2.7% of total assets at the end of Q1 FY2026, up 1.4 pp from a year earlier.
- Accumulated OCI grew in size in 1 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -59.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (91.36M) USD
- Year-over-year change
- +28.6%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (91.36M) | +28.6% |
| FY2024 | 2024-12-31 | (127.89M) | -414.0% |
| FY2023 | 2023-12-31 | (24.88M) | +53.4% |
| FY2022 | 2022-12-31 | (53.43M) | +89.6% |
| FY2021 | 2021-12-31 | (516.01M) | — |
Accumulated OCI vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's Apr 2026 Accumulated OCI of -$103.76M is the 11th highest of the 16 companies compared; the peer median is -$42.55M.
- Its year-over-year change of -59.7% is the 14th highest of 16, against a peer median of -1.0%.
- Accumulated OCI amounts to 2.7% of total assets for ENOV, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $1.63B | +620.7% | — | 14.8% | |
| Jun 2026 | $22.4M | +154.0% | — | 0.8% | |
| Jun 2026 | $1.6M | -96.7% | — | 0.0% | |
| Mar 2026 | -$905K | -2.1% | — | 0.9% | |
| Mar 2026 | -$5.85M | +16.3% | — | 1.8% | |
| Apr 2026 | -$10.33M | +24.0% | — | 4.0% | |
| Jun 2026 | -$20.81M | -1.0% | — | 2.4% | |
| Jul 2026 | -$42.55M | -13.3% | — | 2.3% | |
| Jul 2026 | -$48.2M | -27.9% | — | 3.2% | |
| Feb 2026 | -$100.93M | +22.9% | — | 12.7% | |
| Apr 2026 | -$103.76M | -59.7% | — | 2.7% | |
| Mar 2026 | -$104.8M | +5.5% | — | 26.7% | |
| Jun 2026 | -$140.2M | -9.4% | — | 4.8% | |
| Jul 2026 | -$146.2M | +19.1% | — | 3.7% | |
| Jul 2026 | -$147.52M | -19.7% | — | 2.8% | |
| Sep 2026 | -$151.38B | -90781.7% | — | 5736.8% | |
| Peer median (excluding ENOV) | -$42.55M | -1.0% | — | 3.2% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 680.25M | 24.3M | 36.19M | 48.17M | 36.39M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 254.96M | 267.38M | 291.48M | 407.03M | 442.79M |
| Inventory | 356.23M | 426.64M | 468.83M | 547.12M | 584.38M |
| Other Current Assets | 985.79M | 48.16M | 71.11M | 107.88M | 101.22M |
| Total Current Assets | 2.3B | 795.02M | 896.52M | 1.15B | 1.21B |
| Property, Plant & Equipment (Net) | 311.6M | 303.62M | 334.3M | 473.42M | 579.32M |
| Goodwill | 1.93B | 1.98B | 2.06B | 1.69B | 718.3M |
| Intangible Assets | 1.15B | 1.11B | 1.13B | 1.32B | 1.24B |
| Long-term Investments | 15.42M | 16.5M | 0 | 20.4M | 21.4M |
| Tax Assets | 0 | (16.5M) | 0 | 0 | 0 |
| Other Non-current Assets | 2.8B | 80.29M | 90.26M | 68.38M | 71.95M |
| Total Non-current Assets | 6.21B | 3.48B | 3.61B | 3.57B | 2.63B |
| Total Assets | 8.52B | 4.27B | 4.51B | 4.72B | 3.83B |
| Account Payables | 155.21M | 135.63M | 132.48M | 179.1M | 187.53M |
| Short-term Debt | 29.64M | 243.56M | 21.57M | 20.03M | 59.74M |
| Tax Payables | 72.28M | 13.68M | 14.38M | 21.34M | 0 |
| Deferred Revenue | 9.2M | 3.56M | 2.95M | 6.23M | 6.5M |
| Other Current Liabilities | 736.57M | 101.72M | 114.21M | 188.97M | 212.42M |
| Total Current Liabilities | 1.02B | 565.2M | 369.61M | 529M | 598.47M |
| Long-term Debt | 2.08B | 40M | 466.16M | 1.31B | 1.26B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 102.7M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 695.72M | 166.99M | 204.18M | 263.52M | 321.87M |
| Total Non-current Liabilities | 2.83B | 258.25M | 719.03M | 1.63B | 1.74B |
| Total Liabilities | 3.85B | 823.45M | 1.09B | 2.15B | 2.34B |
| Common Stock | 52K | 54K | 55K | 56K | 57K |
| Retained Earnings | 589.02M | 575.73M | 542.47M | (283.02M) | (1.47B) |
| Accumulated OCI | (516.01M) | (53.43M) | (24.88M) | (127.89M) | (91.36M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 44.06M | 1.72M | 2.31M | 2.07M | 2.26M |
| Total Equity | 4.66B | 3.45B | 3.42B | 2.56B | 1.49B |
| Total Debt | 2.16B | 334.82M | 536.42M | 1.4B | 1.38B |
| Net Debt | 1.48B | 310.52M | 500.23M | 1.36B | 1.34B |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.